Coronado, Pluvio JRychlik, AgnieszkaMartínez-Maestre, Maria ABaquedano, LauraFasero, MaríaGarcía-Arreza, AidaMorales, SaraLubian, Daniel MZapardiel, Ignacio2023-01-252023-01-252018http://hdl.handle.net/10668/11853To assess the impact of lymph node dissection (LND) on morbidity, survival, and cost for intermediate-risk endometrial cancers (IREC). A multicenter retrospective cohort of 720 women with IREC (endometrioid histology with myometrial invasion Both study groups were homogeneous in demographic data and pathologic results. The mean follow-up in patients free of disease was 61.7 months (range, 12.0-275.5). DFS (hazard ratio [HR]=1.34; 95% confidence interval [CI]=0.79-2.28) and OS (HR=0.72; 95% CI=0.42-1.23) were similar in both groups, independently of nodes count. In LND group, positive nodes were found in 10 cases (5.6%). Operating time and late postoperative complications were higher in LND group (p Systematic LND in IREC has no benefit on survival, although it does not show an increase in perioperative morbidity or global cost.enAttribution-NonCommercial 4.0 Internationalhttp://creativecommons.org/licenses/by-nc/4.0/Costs and Cost AnalysisEndometrial NeoplasmsLymph Node ExcisionMorbidityRisk FactorsSurvivalAdultAgedAged, 80 and overCost-Benefit AnalysisEndometrial NeoplasmsFemaleHumansLymph Node ExcisionLymphatic MetastasisMatched-Pair AnalysisMiddle AgedMorbidityNeoplasm StagingPostoperative ComplicationsRetrospective StudiesRisk FactorsSeverity of Illness IndexSurvival AnalysisTreatment OutcomeUterine Neoplasmsresearch article29185259open access10.3802/jgo.2018.29.e12005-0399PMC5709519https://doi.org/10.3802/jgo.2018.29.e1https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5709519/pdf